Full-Time
Business Development Lead
Provider
Updated on 5/9/2026
Verily
1,001-5,000 employees
Precision health tech leveraging data science
Compensation Overview
$179k - $263k/yr
No H1B Sponsorship
Remote in USA
Remote
 Business & Strategy (1) |
|---|
- MBA and/or other advanced degree and 10+ years of experience working in a business development or strategic partnerships role with specific experience selling innovative healthcare technology solutions
- Deal sheet with a proven record of strategic and revenue generating partnerships and collaborations, demonstrating a track record of managing and closing transactions
- Demonstrated ability to simultaneously lead multiple deals and complex deal structures from deal inception to successful execution with strong strategic and analytical skill and ability to drive exploration into new and emerging areas using creative problem solving skills and executive-level engagement
- Numerous pre-existing and deep relationships across key decision-makers within the Provider / Health System space and adjacent market segments
- Comfort with ambiguity, with a desire to help cross-functional teams achieve clarity and alignment, and a proven track record of working with cross-functional teams to achieve company objectives
- Join a team of Business Development Leads charged with identifying, architecting, negotiating, and closing critical and complex strategic collaborations, working across Verily’s lines of business and consistent with the business development strategy and objectives; gain key internal stakeholder and senior leadership support; and collaborate with Verily’s cross-functional teams to drive growth
- Develop a deep understanding of the different lines of business, particularly our Pre (Workbench, Refinery, Exchange), Viewpoint, Verily Me, and Lifelong products and capabilities across Verily. Use key learnings to help inform areas for future investment. Manage how the market perceives the company and how new partners/collaborators are perceived within Verily
- Develop, manage and own a robust prospect pipeline, KPIs and outcomes. Communicate well and partner effectively with colleagues within the Business Development & Strategic Partnerships function and the broader Commercial team on opportunities and obstacles
- Work closely with finance, legal, product, engineering, marketing, and science teams across a range of transaction types, including long-term collaborations, first-of-kind transactions, and multi-party agreements. Evaluate opportunities, conduct due diligence, negotiate agreement terms and present recommendations to senior leadership
- Work with Commercial leadership to define strategic requirements for strategic opportunities, determine appropriateness and operational fit with existing strategy; develop, nurture and manage a pipeline of major deals
- Experience in regulated environments and in managing and structuring partnerships and long-term collaborations within Provider / Health System and related verticals
- Familiarity working in a fast-paced, rapidly changing, startup-like environment
- Experience presenting and delivering succinct messages to external audiences
Verily Life Sciences uses data science and clinical expertise to improve health outcomes through precision health. It combines medical, lifestyle, and environmental data to tailor interventions, offering products like the Baseline Platform for clinical research and COVID-19 testing, care management solutions, and medical devices. It differentiates itself by integrating diverse data at scale, pursuing health equity through Onduo, and collaborating with public sector partners while maintaining strong data security and privacy. The goal is to uncover new health insights and bring precision health to everyone, improving health outcomes across populations.
Company Size
1,001-5,000
Company Stage
Late Stage VC
Total Funding
$3.8B
Headquarters
San Francisco, California
Founded
2015
Simplify's Take
What believers are saying
- $300M funding from Series X Capital ends Alphabet control, boosts AI expansion.
- Nvidia integration accelerates multimodal data processing in Pre platform.
- Samsung HIMSS26 partnership unlocks wearable data for real-world evidence generation.
What critics are saying
- Sloan lawsuit exposes HIPAA breaches affecting 25,000 Onduo patients since 2017.
- HHS OCR fines hit Verily for failing 60-day breach notifications until 2026.
- Tempus steals NIH contracts as Verily's privacy scandals erode partner trust.
What makes Verily unique
- Verily Pre platform integrates Galaxy Watch8 data with AI for clinical research.
- Verily Workbench on AWS enables compliant AI analysis for NIH All of Us.
- Segmed partnership adds 150 million de-identified imaging exams to Pre Exchange.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Verily who can refer or advise you
Benefits
Company Equity
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 0%Verily Health has announced that Verily Workbench, its scalable trusted research environment for biomedical data analysis and AI development, is now generally available on Amazon Web Services. The platform enables researchers to analyse healthcare data with built-in compliance and integrated AI tools. Workbench offers zero cloud cost markup, allowing organisations to use existing AWS accounts and negotiated rates. The platform includes native integration with NVIDIA AI tools and supports multicloud operations across AWS and Google Cloud Platform. Researchers can access free standard tier accounts through Verily's Exchange solution. The platform currently serves life sciences, health system and government customers, including the NIH's All of Us Research Programme, which supports over 20,000 researchers worldwide. Verily holds SOC 2 Type 2 and ISO/IEC 27001 certifications.
Dallas-Based Verily raises $300M, ending Alphabet's controlling stake. Verily graduated from Google X 10 years ago as one of Alphabet's earliest "Other Bets," focusing on breakthrough science and health tech innovation. Its new round was led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz, and other investors. The lobby of Verily's headquarters at Cypress Waters in Dallas. [Photo: Verily] Dallas-based Verily has raised a new $300 million investment round led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz, and other investors, for the next phase of its precision health AI strategy. With this funding round, Alphabet will now be a significant minority investor in Verily, while no longer having a controlling stake. "Today is an important step in our mission to bring the promise of precision health to everyone," said Stephen Gillett, chairman and CEO of Verily,. "From research to care, our customers need solutions that bring the best of clinical and scientific rigor together with AI to deliver the next generation of healthcare - one that is as precise as it is personal." "Series X Capital, Alphabet, UCHealth, the University of Colorado Anschutz and our many investors will be fantastic partners in this transformation of healthcare," Gillett added in a statement. With the investment, Verily has transitioned its legal structure from an LLC to a corporation, and will now operate as Verily Health Inc. The company said it aims to boost its AI-native precision health platform strategy and roadmap to help customers streamline their healthcare data, while modeling and deploying actionable intelligence into research and care workflows. Verily is headquartered in the Cypress Waters development in Dallas, just southeast of Coppell. The company relocated its HQ from South San Francisco in 2024, bridging its East and West Coast operations in North Texas while maintaining its presence in the Bay Area. Using AI to transform healthcare. Recently, Verily has established several commercial partnerships, including a new collaboration with Samsung's Galaxy Watch to help life sciences customers advance clinical research through biomarker development on the Pre platform. The company has also announced a strategic partnership with Salesforce for the integration of the Verily Pre Platform with Agentforce Health to fuel enterprise precision health solutions. Verily said the new partnerships are strengthened by its recent collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience, who are using the Verily Pre platform for AI-driven research and care transformation. Gideon Yu, founder and managing partner of Series X Capital, said his firm "was established in collaboration with Google's X, The Moonshot Factory, to scale moonshot technologies into consequential, world-changing companies." He added that his firm is "extremely excited to lead this milestone round for Verily, as they drive commercial momentum as a leader in precision health." 'A generational opportunity' Graduating from Google X 10 years ago as one of Alphabet's earliest "Other Bets," Verily focuses on breakthrough science and health tech innovation. "At Alphabet, we applaud Verily's tenacity in using technology to address longstanding challenges in the healthcare industry," said Ruth Porat, president and. chief investment officer at Alphabet and Google. "Bringing in new investors, alongside Alphabet's ongoing involvement, enables Verily to further scale the business to help improve patient outcomes and lower the cost of healthcare delivery through their AI health platform." Richard Zane, MD, UCHealth chief medical and innovation Officer, said that collaborating with Verily to craft a data framework "creates a generational opportunity" to improve medicine. "This collaboration helps unlock the long-promised potential of personalized care," Zane added, "benefiting our patients and, ultimately, all patients. It will save lives, and we're eager to get started." Other recent moves by Verily. Last October, Verily launched a new consumer health app, Verily Me, designed to close gaps in care and enable people to stay informed and engaged in their health journey over time. Last April, Verily received a $14.7 million grant from The Michael J. Fox Foundation for Parkinson's Research. The grant's goal is to generate a comprehensive molecular dataset to advance Parkinson's disease research. Track Dallas-Fort Worth's business and innovation landscape with its curated news in your inbox Tuesday-Thursday. One quick signup, and you're done. R E A D N E X T. * The Last Word: Arete Health CEO On a First-of-Its-Kind Health and Wellness Program for Dallas Creatives Creatives Care Dallas brings virtual care, behavioral health, 2,000+ medications with zero copay, and more to Dallas County's gig workers. The community initiative is powered by Arete Health Shield in partnership with the Dallas Music Office. * Calendar: Not-to-Miss Events for Innovators in Dallas-Fort Worth North Texas has plenty to see, hear, and watch. Here are its editors' picks. Plus, you'll find more selections to "save the date." * Alphabet-Owned Verily Launches AI-Powered App to Manage Healthcare and Personalize Insights Unveiled at HLTH USA 2025, the Dallas-based precision health company's Verily Me app blends clinical guidance and AI-driven tools to help people stay informed, connected, and proactive in managing their health. * North Texas Innovation Is Boundary-Breaking. Nominations for the Awards That Prove It Close Sept. 12 D CEO and Dallas Innovates have expanded The Innovation Awards 2026 with more individual and company categories this year. Now is your chance to be part of the region's defining recognition for innovators. * SVP Dallas Names Catherine Cuellar as Its Next CEO A familiar figure in Dallas arts, civic innovation, and public service, Cuellar will succeed longtime CEO Tony Fleo following a months-long search as Social Venture Partners Dallas plans its next 25 years. Share via:
Exclusive: verily raises $300M, sheds Alphabet's majority control. Health tech correspondent. Verily has raised $300 million in new, outside funding that ends parent company Alphabet's controlling position in the healthcare innovation company, Endpoints News has learned... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Dallas, TX – March 19, 2026 – Verily today announced a $300 million investment round led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz and other investors, to advance the next phase of its precision health AI strategy.
Samsung partners with Verily Life Sciences to utilize Galaxy Watch8 data. At HIMSS26, Verily Life Sciences announced a partnership with Samsung Electronics to combine Galaxy Watch8 with Verily's precision health platform to further clinical research. By Jessica Hagen | March 10, 2026 | 11:59 AM Photo: Courtesy of Samsung LAS VEGAS - At the 2026 HIMSS Global Health Conference & Exposition here, Samsung Electronics America announced a partnership with Verily Life Sciences to connect Verily's precision health platform, Pre, with Samsung's Galaxy Watch8 to monitor real-world populations and generate evidence to assist in research for life sciences and governments. Pre is an AI-enabled offering that processes structured and unstructured multimodal data for AI deployment, workflow orchestration and analytics. The partnership will integrate sensor data from the Galaxy Watch and make it accessible in its Viewpoint Evidence tool, built on the company's Pre platform. "Sponsors will use Verily Pre data solutions including Refinery for data harmonization and Workbench for analysis, modeling and activation. Verily will provide AI/ML-based analytics and digital measure expertise, paired with comprehensive clinical trial support across regulatory, development, operations and compliance," Verily said in a statement. The companies aim to help life sciences organizations and governments accelerate research using health analytics and customer-grade wearable data. The partners say the collaboration will allow researchers to combine Verily's longitudinal datasets from consented participants with Samsung's data, customize research capabilities by allowing sponsors to run their own studies, and recruit and engage Samsung users for research participation. As part of the collaboration, the partners said they will further explore jointly developing new solutions for clinical research.